Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
ConditionLymphatic Malformation
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age1-18
SponsorWest China Hospital
About this trial
The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of cystic lymphatic malformation.
Eligibility criteria
Qualifiers
Male and female;
Between 0 and 18 years of age;
Disqualifiers
Patients contraindicated for the administration of sirolimus (e.g., those with an allergy to sirolimus or other rapamycin analog)
Exposure to chemotherapy, embolization, corticosteroids, propranolol, sclerotherapy or any other investigational agents within 1 weeks before enrolment on study;
Patients had a history of a major surgery within 2 weeks before enrollment;
Patients who have a history of treatment with sirolimus or other mTOR inhibitor;
Trial design
Treatments tested in this trial
- Sirolimus (RAPAMUNE)
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
West China Hospital
Lead sponsor
Sichuan University
Sponsor institution
Source ClinicalTrials.gov